Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
May 31 IONS Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31 IONS Ionis hereditary angioedema therapy succeeds in late-stage trials
May 31 IONS Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 31 BMY Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
May 30 BMY Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
May 30 BMY Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
May 30 BMY Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
May 29 BMY Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
May 29 BMY Bristol-Myers gets EU approval for Opdivo for bladder cancer
May 29 BMY BMS secures another EC approval for Opdivo combination
May 29 BMY BMS stakes $80m on Prothena’s neurodegenerative candidate
May 29 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 28 IONS Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28 BMY ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
May 28 IONS Ionis to hold donidalorsen Phase 3 data webcast
May 25 BMY Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags